Of the 18 enrolled patients, none underwent dose modifications or reductions, but treatment delay was implemented on 2 (11.1%) patients because of adverse events: 1 patient in the 10 mg cohort omitted doses for 5 days due to grade 1 nasopharyngitis and 1 patient treated at dose level 50 mg omitted treatment for 10 days due to grade 1 elevation of AST and ALT. Here, GPT is linked to nasopharyngitis.